Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Radical Resection Effective against Pancreatic Cancer

By HospiMedica staff writers
Posted on 07 Aug 2007
Radical surgical resection, considered to be the only curative approach in the treatment of pancreatic cancer, appears to be worthwhile in appropriate patients, claims a new study.

Researchers at the Michael E. More...
DeBakey Veterans Affairs (VA) Medical Center (Houston, TX, USA) studied 32,348 cases of pancreatic cancer that occurred between 1987 and 2001, using data from nine registries of the Surveillance Epidemiology and End Results (SEER) program. The researchers examined the predictors of receiving curative intent surgery (CIS) as well as the survival of patients receiving CIS. In all, 3,545 of the patients (10.9%) received CIS. This proportion decreased significantly with age and with advanced disease stage, but increased over time. Although there were significant regional differences, the proportion of patients undergoing CIS rose from 7.5% in 1987 to 1989 to 13.4% in 1999 to 2001.

The researchers found that survival rates at one year were 53% for patients undergoing CIS compared with 20.6% among those who did not receive CIS; corresponding figures at three years were 12.2% versus 2.0%. In addition, although CIS rates were similar across racial groups, being black was an independent predictor of shorter survival. Early stage disease, female gender, younger age, geographic location, and more recent time periods were found to be predictors of receiving CIS. The study was reported in the July 2007 issue of the American Journal of Gastroenterology.

"This study shows that patients receiving curative intent surgery for pancreatic cancer do better than those who do not,” said lead author Dr. Yasser Shaib. "More aggressive surgical therapy should be considered in eligible patients. In addition, efforts should focus on detecting pancreatic cancer early so that curative surgery can be offered.


Related Links:
Michael E. DeBakey VA Medical Center

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.